ResearchOur PeopleMark C. Hornbrook

Mark C. Hornbrook, PhD

Mark C. Hornbrook, PhD, is a health economist and Chief Scientist at Kaiser Permanente's Center for Health Research. Dr. Hornbrook is a recognized expert in research focusing on the determinants of medical care utilization, expenditures, economic burden, health outcomes, comparative effectiveness, and cost effectiveness.

Dr. Hornbrook has served on the Board of Directors of the HMO Research Network since its founding. He is on the Executive Committee of the Cancer Research Network, a collaboration among 10 research centers affiliated with non-profit integrated health care delivery systems across the nation. Dr. Hornbrook also co-leads the CRN Health Care Quality and Cost scientific working group. He has significant expertise in cost-effectiveness analysis, using both secondary and clinical-trial data. He has evaluated the cost effectiveness of routine screening of blood donations for hepatitis, influenza vaccination programs, group and Internet-based self-help programs for depressed adolescents, hospital-based smoking cessation programs, and echocardiography for post-stroke evaluation.

He has conducted three randomized controlled trials (RCTs) focused on elderly participants, including two RCTs combining environmental risk reduction with exercise interventions to prevent falls, and another RCT of a home health intervention for families with frail elderly members needing personal and nursing care. Dr. Hornbrook also serves as the principal investigator of a four-site study to assess the incremental medical care costs of cancer in integrated care systems and comparing HMO cancer costs with SEER-Medicare costs to assess how financial incentives in capitated and fee-for-service systems affect Medicare beneficiaries.

Additionally, Dr. Hornbrook is working on a multi-site, mixed-methods research program addressing HRQOL of colorectal cancer survivors that have led to numerous subanalyses and publications.

Dr. Hornbrook has published in many areas, including cost and utilization analysis, illness episode grouping methods, economic evaluation methods, patient classification models, health status measurement, predictive modeling, and health-based remuneration systems. His work has produced nearly 200 peer-reviewed journal articles and book chapters. He served as a commissioner on the Physician Payment Review Commission (PPRC), Congress of the United States, from 1986 through 1990. During his tenure, the PPRC developed the Medicare Fee Schedule and Volume Performance System reforms of the Medicare Part B payment system. Dr. Hornbrook served as a member of the National Committee on Vital and Health Statistics from 2008-2012, where the key policy issues being addressed related to guidelines and incentives for installing electronic medical record systems.

Recent Publications

  • Carroll N, Delate T, Menter A, Hornbrook MC, Kushi L, Bowles EJ, Loggers ET, Ritzwoller DP. Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer. Journal of Oncology Practice. [Epub 2015 Aug 4]
  • Chongpison Y, Hornbrook MC, Harris RB, Herrinton LJ, Gerald JK, Grant M, Bulkley JE, Wendel CS, Krouse RS. Self-reported depression and perceived financial burden among long-term rectal cancer survivors. Psychooncol. [Epub 2015 Sep 14] PMID:26365584 NIHMS714839.
  • Sharma AJ, Vesco KK, Bulkley J, Callaghan WM, Bruce FC, Staab J, Hornbrook MC, Berg CJ. Associations of Gestational Weight Gain with Preterm Birth among Underweight and Normal Weight Women. Maternal and Child Health J 2015 Feb 2; 19(2). [Epub 2015 Feb 2]
  • Sun V, Grant M, Wendel CS, McMullen CK, Bulkley JE, Altschuler A, Ramirez M, Baldwin CM, Herrinton LJ, Hornbrook MC, Krouse RS. Dietary and Behavioral Adjustments to Manage Bowel Dysfunction After Surgery in Long-Term Colorectal Cancer Survivors. Ann Surg Oncol. 2015 Jul 10. [Epub ahead of print]
  • Delate T, Won K, Carroll NM, Kushi L, Hornbrook M, Bowles EJA, Menter A, Loggers ET, Ritzwoller D. Factors associated with first-line bevacizumab use inadvanced non-squamous, non-small cell lung cancer. Journal of Cancer Research & Therapy 2014; 2(1):1-8

Follow Us